Newron Pharmaceuticals Reports Annual Results and Announces Board Transition

Newron reports 2025 results, extends EIB debt to 2028, and advances Evenamide Phase III trials for schizophrenia. AGM to renew board with new directors.

Italian biopharmaceutical firm Newron SpA released its full-year 2025 financial results and its 2026 outlook on March 24, 2026. The announcement coincided with the publication of the complete agenda for its upcoming Annual General Meeting in April, presenting shareholders with a significant update on multiple fronts.

Key Clinical Program and Financial Metrics in Focus

Investor attention is currently centered on the progress of the company's pivotal Phase III program for Evenamide, its investigational therapy for treatment-resistant schizophrenia. The ENIGMA-TRS 1 study, which commenced in August 2025, is evaluating Evenamide as an adjunctive therapy in at least 600 patients. A separate third Phase III trial is underway in Japan through the company's Asian partner, EA Pharma.

Financially, market participants are monitoring Xadago sales figures, the advancement of the ENIGMA-TRS studies, and the company's remaining liquidity. Newron is scheduled to present initial scientific data this week, with three posters planned for the SIRS congress in Florence from March 26-28. These will include Phase III updates and new findings on patient social functioning.

Strategic Financial Maneuvers Extend Runway

In a move to bolster its financial position just days before the earnings release, Newron reached an agreement with the European Investment Bank (EIB) on March 19, 2026. The deal extends the maturity dates for all outstanding tranches from a 2018 financing agreement, with the new deadlines now running until June 28, 2028. The final signing of the contract remains pending.

This debt extension is part of a broader financing strategy. In February 2026, a group of investors subscribed to new shares at a price of 19.24 euros per share, providing gross proceeds of up to 15 million euros. An additional tranche of 11 million euros is contingent upon the 12-week results from the pivotal ENIGMA-TRS studies, expected no later than the end of November 2026.

Board of Directors Sees Renewal

The Annual General Meeting scheduled for April 23, 2026, will feature a renewal of the company's board. Two long-serving members, Patrick Langlois and Luca Benatti, will not stand for re-election. Shareholders will vote on the proposed appointments of George Garibaldi and Paolo Zocchi as new independent, non-executive directors.

Garibaldi brings over three decades of experience in CNS drug development from roles at Hoffmann-La Roche, Janssen, and Novartis, and is a co-founder of Noema Pharma. Zocchi offers more than 35 years of international experience as a Senior Partner at Ernst & Young, where he advised major pharmaceutical clients including Sanofi and Bayer.

The company's share price currently trades approximately 49% below its 52-week high of 32.95 euros, indicating the market is awaiting conclusive clinical data before determining its next directional move.